

MEMORANDUM OF UNDERSTANDING BETWEEN
THE FOOD AND DRUG ADMINISTRATION AND THE NATIONAL TREASURY
EMPLOYEES UNION

This memorandum of understanding (MOU) was agreed upon pursuant to Article 52 of the Food and Drug Administration (FDA)/National Treasury Employees Union (NTEU) Collective Bargaining Agreement (CBA). It establishes procedures for administering parking for bargaining unit employees at the FDA White Oak facility. This memorandum is effective upon approval by the agency head pursuant to 5 U.S.C. § 7114(c) or on the 31st day after execution by the parties, whichever comes first. It may be revised by mutual agreement of the parties, at the request of either party if there are changes in circumstances relative to parking, or consistent with the applicable collective bargaining agreement.

The parties agree that employee parking shall be administered in accordance with applicable Government-wide regulations (currently Federal Management Regulation, Part 102-74) and this agreement. Further, the parties agree as follows:

1. The FDA will manage handicapped parking so as to prioritize spaces, to the extent reasonably feasible, for the most severely handicapped employees.
2. The FDA will manage parking associated with GSA vehicles, White Oak Guard service and White Oak campus visitors.
3. Carpools and vanpools will receive priority parking pursuant to applicable regulations (currently the Federal Management Regulation, Part 102.74, Subpart B, § 102-74-305(c)).
4. The FDA will reserve five (5) percent of all currently available parking spaces, which equals 5147 spaces. The FDA will determine the use of those spaces. However, such spaces can only be assigned to non-bargaining unit federal employees. Any exceptions will be decided by the White Oak Parking Committee. The FDA may use and locate up to 50 additional spaces to be designated by signage as "reserved" for use at the discretion of management.
5. Twenty spaces will be reserved for NTEU Chapter 282 representatives. These spaces will be co-located with the reserved

spaces referred to in paragraph 4 above. NTEU will provide the FDA White Oak parking authority with a completed parking permit for each of these 20 spaces.

6. All remaining parking not encumbered through items 1, 2, 3, 4 and 5 above will be available on a first come, first serve basis.
7. The FDA will provide employees with a 60-day advance notice prior to the open season for parking applications for those employees who receive parking spaces pursuant to items 1, 2, 3, 4, and 5.
8. The parties recognize that the FDA does not have control over certain aspects of the White Oak Facility, such as lighting for the parking facilities, which is the responsibility of the General Services Administration. However, to enhance safety, the FDA will take such actions as are within its discretion to ensure that the parking facilities have proper lighting twenty-four (24) hours a day.
9. The FDA will take actions to the extent of its discretion to ensure that appropriate and adequate security is provided in parking areas during the hours during which employees work.
10. The parties agree to establish a joint labor-management White Oak Parking Committee to address parking issues that may arise in the course of administering this agreement. The committee shall comprise four members to be appointed by each party and shall meet as often as is mutually agreed upon by the parties. However, the parties agree that such meetings shall be held at least quarterly unless both parties agree that no meeting is necessary.
11. The Agency will provide to NTEU Chapter 282, at least one week prior to the scheduled quarterly meeting of the joint labor-management White Oak Parking Committee, a list of reported safety incidents occurring in White Oak parking areas since the last meeting. The list will be in a summary format that excludes information protected by

the Privacy Act and will include incidents reported to management and maintained by the FDA Environment, Safety and Health Staff.

For the NTEU: ,

Geruice Dredler

Feb. 13, 2007

For the FDA:

RJ ASH

Feb 13, 2007

Executed: